Frontiers in Cellular Neuroscience (Feb 2021)

Organoid Models of Glioblastoma and Their Role in Drug Discovery

  • Matthew J. Rybin,
  • Matthew J. Rybin,
  • Matthew J. Rybin,
  • Michael E. Ivan,
  • Michael E. Ivan,
  • Nagi G. Ayad,
  • Nagi G. Ayad,
  • Nagi G. Ayad,
  • Zane Zeier,
  • Zane Zeier,
  • Zane Zeier

DOI
https://doi.org/10.3389/fncel.2021.605255
Journal volume & issue
Vol. 15

Abstract

Read online

Glioblastoma (GBM) is a devastating adult brain cancer with high rates of recurrence and treatment resistance. Cellular heterogeneity and extensive invasion of surrounding brain tissues are characteristic features of GBM that contribute to its intractability. Current GBM model systems do not recapitulate some of the complex features of GBM and have not produced sufficiently-effective treatments. This has cast doubt on the effectiveness of current GBM models and drug discovery paradigms. In search of alternative pre-clinical GBM models, various 3D organoid-based GBM model systems have been developed using human cells. The scalability of these systems and potential to more accurately model characteristic features of GBM, provide promising new avenues for pre-clinical GBM research and drug discovery efforts. Here, we review the current suite of organoid-GBM models, their individual strengths and weaknesses, and discuss their future applications with an emphasis on compound screening.

Keywords